How does BCRX *'s PS Ratio compare to its peers?

BCRX * is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (27.7x).

How does BCRX *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

BCRX * is good value based on its Price-To-Sales Ratio (4.6x) compared to the Global Biotechs industry average (9.8x).

What is BCRX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate BCRX *'s Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of BCRX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BCRX * (MX$170) is trading below our estimate of [[fair value]] (MX$857.89)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

BioCryst Pharmaceuticals (BMV:BCRX *) - Stock Price, News & Analysis

BCRX * Stock Overview

A biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.

About the company

BCRX * fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 80.2% below our estimate of its fair value

Earnings are forecast to grow 70.45% per year

Risk Analysis

Negative shareholders equity

Shares are highly illiquid

Shareholders have been diluted in the past year

BioCryst Pharmaceuticals, Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$25.0b

Nurix Therapeutics

NasdaqGM:NRIX

US$1.7b

Bicycle Therapeutics

NasdaqGS:BCYC

US$1.6b

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$1.8b

Price History & Performance

Summary of all time highs, changes and price drops for BioCryst Pharmaceuticals
Historical stock prices
Current Share Price	US$170.00
52 Week High	US$170.00
52 Week Low	US$98.29
Beta	1.88
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-45.11%
5 Year Change	n/a
Change since IPO	149.82%

Recent updates

Shareholder Returns

	BCRX *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how BCRX * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how BCRX * performed against the MX Market.

Price Volatility

Is BCRX *'s price volatile compared to industry and market?
BCRX * volatility
BCRX * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: BCRX *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine BCRX *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	536	Jon Stonehouse	www.biocryst.com

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases.

BioCryst Pharmaceuticals, Inc. Fundamentals Summary

How do BioCryst Pharmaceuticals's earnings and revenue compare to its market cap?
BCRX * fundamental statistics
Market cap	Mex$35.36b
Earnings (TTM)	-Mex$2.96b
Revenue (TTM)	Mex$7.75b

4.6x

P/S Ratio

-12.0x

P/E Ratio

Is BCRX * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BCRX * income statement (TTM)
Revenue	US$382.24m
Cost of Revenue	US$202.37m
Gross Profit	US$179.86m
Other Expenses	US$325.80m
Earnings	-US$145.93m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 04, 2024

Earnings per share (EPS)	-0.71
Gross Margin	47.06%
Net Profit Margin	-38.18%
Debt/Equity Ratio	-176.1%

How did BCRX * perform over the long term?

See historical performance and comparison

BCRX * Stock Overview

Rewards

Risk Analysis

BioCryst Pharmaceuticals, Inc. Competitors

BMV:LAB B

Mex$25.0b

NasdaqGM:NRIX

US$1.7b

NasdaqGS:BCYC

US$1.6b

NasdaqGS:RXRX

US$1.8b

Price History & Performance

Recent News & Updates

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Recent updates

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022)

Forecast to breakeven in 2026

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Forecast to breakeven in 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022)

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

High number of new directors

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia

BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021)

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

High number of new directors

BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)

BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250

Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic